Evidence map›Paper›PMID 32839411›Full record

ArticleInternational journal of molecular sciences2020

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with

Tomokazu Ohishi, Yukinari Kato, Mika K Kaneko, Shun-Ichi Ohba, Hiroyuki Inoue, Akiko Harakawa, Manabu Kawada

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Current Targeted Therapy for Metastatic Colorectal Cancer.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tomokazu OhishiInstitute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation and 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.ORCID 0000-0002-9039-4474
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.ORCID 0000-0001-5385-8201
Mika K KanekoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
Shun-Ichi OhbaInstitute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation and 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.
Hiroyuki InoueInstitute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation and 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.
Akiko HarakawaInstitute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation and 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.
Manabu KawadaInstitute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation and 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.
Microbial Chemistry Research Foundation · JPTohoku University · JP

Funding

Japan Agency for Medical Research and Development 19cm0106213h0004Japan Agency for Medical Research and Development JP19ae0101028Japan Agency for Medical Research and Development JP19am0101078Japan Agency for Medical Research and Development JP19am0401013Japan Society for the Promotion of Science 17K07299Japan Society for the Promotion of Science 18K08693Japan Society for the Promotion of Science 19K07705
6 · The paper itself

Abstract

The now clinically-used anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have demonstrated significant efficacy only in patients with metastatic colorectal cancer (mCRC), with wild-type Kirsten rat sarcoma viral oncogene homolog (

Indexed as

MutationAnimalsAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityAntineoplastic Agents, ImmunologicalCell Line, TumorCell ProliferationCHO CellsColorectal NeoplasmsComplement System ProteinsCricetulusErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHCT116 CellsHumansAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalComplement System ProteinsEGFR protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)antibody-dependent cell cytotoxicitycolorectal cancercomplement-dependent cytotoxicityepidermal growth factor receptormetastasis

Identifiers

PMID32839411
PMCPMC7504481
OpenAlexW3081149577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.